WO2024039883A3 - Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms - Google Patents

Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms Download PDF

Info

Publication number
WO2024039883A3
WO2024039883A3 PCT/US2023/030634 US2023030634W WO2024039883A3 WO 2024039883 A3 WO2024039883 A3 WO 2024039883A3 US 2023030634 W US2023030634 W US 2023030634W WO 2024039883 A3 WO2024039883 A3 WO 2024039883A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloproliferative
compositions
methods
treat
neoplasms
Prior art date
Application number
PCT/US2023/030634
Other languages
French (fr)
Other versions
WO2024039883A2 (en
Inventor
Stephen Gately
Original Assignee
Translational Drug Development Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Drug Development Llc filed Critical Translational Drug Development Llc
Publication of WO2024039883A2 publication Critical patent/WO2024039883A2/en
Publication of WO2024039883A3 publication Critical patent/WO2024039883A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions useful for treating a subject suffering from a myeloproliferative disorder or disease, or from a disease or condition associated with myeloproliferative neoplasms, and methods of such treatment using the compositions, wherein the compositions include an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
PCT/US2023/030634 2022-08-19 2023-08-18 Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms WO2024039883A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263399616P 2022-08-19 2022-08-19
US63/399,616 2022-08-19

Publications (2)

Publication Number Publication Date
WO2024039883A2 WO2024039883A2 (en) 2024-02-22
WO2024039883A3 true WO2024039883A3 (en) 2024-03-28

Family

ID=89942213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/030634 WO2024039883A2 (en) 2022-08-19 2023-08-18 Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms

Country Status (1)

Country Link
WO (1) WO2024039883A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190248744A1 (en) * 2016-10-24 2019-08-15 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
WO2021247064A1 (en) * 2020-06-03 2021-12-09 Incyte Corporation Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190248744A1 (en) * 2016-10-24 2019-08-15 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
WO2021247064A1 (en) * 2020-06-03 2021-12-09 Incyte Corporation Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Also Published As

Publication number Publication date
WO2024039883A2 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
ZA202109010B (en) Compounds and methods for the treatment of covid-19
EA201190303A1 (en) DERIVATIVES 1,2,4-TRIAZOLO [4,3-a] Pyridine and their use for the treatment or prevention of neurological and psychiatric disorders
CR20230310A (en) Prmt5 inhibitors
DE60329990D1 (en) MITOTIC KINESINE HEMMER
MX2022000244A (en) PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF.
MX2019001036A (en) Treatment and prevention of sleep disorders.
TW200639159A (en) Treatment of pain
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
MX2022002597A (en) Methods of treating epilepsy using the same.
EA202192122A1 (en) COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION
WO2020033838A3 (en) Treatment of egfr-mutant cancer
AU2017261286A1 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
PH12018501489A1 (en) Compounds and compositions for the treatment of cryptosporidiosis
MX2022013650A (en) Imidazopyrimidines as modulators of il-17.
MX2021012105A (en) Pyrrole compounds.
MX2023003332A (en) Line-1 inhibitors to treat disease.
WO2024039883A3 (en) Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
MX2022002446A (en) Perk inhibiting pyrrolopyrimidine compounds.
MX2021009082A (en) Chemical compounds.
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
WO2023077125A3 (en) Azepino-indoles for the treatment of neurological and psychiatric disorders
MX2023004998A (en) Method of treating cancers with alkyne substituted quinazoline derivatives.
EA202193211A1 (en) TREATMENT OF SYNUCLEOPATHIES
MX2022012632A (en) Use of bromodomain inhibitors for treatment of huntington's disease.
MX2022012404A (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855523

Country of ref document: EP

Kind code of ref document: A2